Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
H. Li, G. Schmid-Bindert, D. Wang, Y. Zhao +3 more
2011Advances in Medical Sciences84 citations
Semantic Scholar
Researcher profile · Semantic Scholar
H. Li, G. Schmid-Bindert, D. Wang, Y. Zhao +3 more
X.-H. Zhang, N. Jia, X.-Y. Zhao, G. Tang +5 more
D. Wang, H. Li, H. Yuan, M. Zheng +3 more
T. Wang, Yue-Song Pan, Jin-Xi Lin, R. Anand +7 more
H. Li, D. Wang, H. Wang, P. Chen
D. Wang, H. Li, X. Ge, R. Wang
H. Xie, S.-Y. Tang, H. Li, X.-H. Luo +3 more
X. Cao, X. Gao, W. Li, P. Liu +3 more
H. Li, Q. Zhu, Chang-Qing Ke, D. Wang +1 more
C. Cheng, H. Li, J. Zhang, X. Ben +4 more
X. Tu, L. Zhang, W. Chen, D. Wang +4 more
D. Wang, Y. Zhang, J. Lin, H. Li +2 more
J. Ma, H. Li, D. Wang, Mw W. Fu +1 more
Hong-feng Yuan, D. Wang, H. Li, X. Pei
Xue-Ying Shi, Zhao-Lai Ma, D. Wang, Y. Liang +2 more